文献速递前列腺增生与排尿功能障碍男科与性医学

度他雄胺与他达拉非固定剂量复方对比单药治疗良性前列腺增生的随机III期试验

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial.
PubMed 文献 · BJU Int · 2026-02-10

这项III期随机试验纳入667例BPH患者,比较度他雄胺0.5mg/他达拉非5mg固定剂量复方(FDC)与两种单药治疗48周的疗效与安全性。主要终点IPSS总分变化显示FDC组优于两个单药组(LSMD分别为-5.09和-5.29,均P<0.001),生活质量改善最明显,安全谱可接受。

要点

  • FDC 0.5/5mg组48周IPSS总分较基线下降-9.49,显著优于度他雄胺单药(-4.40)和他达拉非单药(-4.24)。
  • FDC组生活质量改善最明显,但最大尿流率和残余尿量组间差异无统计学意义。
  • FDC组TEAE发生率32.88%,度他雄胺组21.20%,他达拉非组26.48%,严重不良事件少见。

核心结论

  • 在BPH患者中,度他雄胺0.5mg/他达拉非5mg固定剂量复方在改善IPSS总分方面优于度他雄胺单药和他达拉非单药,且安全谱可接受。

研究设计与样本

  • III期随机对照试验,筛查洗脱后按基线IPSS分层,1:1:1随机分配至FDC 0.5/5mg、度他雄胺0.5mg或他达拉非5mg组,治疗48周。
  • 共入组667例患者,其中619例纳入疗效分析,655例纳入安全性分析。

主要发现

  • 48周时IPSS总分较基线LS均值(se)变化:FDC组-9.49(0.37),度他雄胺组-4.40(0.37),LSMD -5.09(95%CI -6.13至-4.50,P<0.001)。
  • 48周时IPSS总分较基线LS均值(se)变化:FDC组-9.53(0.36),他达拉非组-4.24(0.37),LSMD -5.29(95%CI -6.30至-4.27,P<0.001)。
  • FDC组生活质量改善最明显;最大尿流率和残余尿量在所有组均有改善,但组间差异无统计学意义。
  • FDC组与度他雄胺组比较,IIEF-EF总分48周较基线变化LSMD为4.03(95%CI 2.35至-5.71,P<0.05)。
  • 安全性分析中TEAE发生率:FDC组32.88%,度他雄胺组21.20%,他达拉非组26.48%,严重不良事件少见。

临床怎么用

  • 对于BPH合并勃起功能障碍且适合联合治疗的患者,可考虑度他雄胺0.5mg/他达拉非5mg固定剂量复方以同时改善下尿路症状和生活质量。
  • 治疗期间需关注TEAE发生风险,FDC组TEAE发生率高于两个单药组,但严重不良事件少见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of a fixed-dose combination (FDC) of dutasteride and tadalafil vs monotherapy in patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: This phase III trial enrolled 667 patients. After screening and washout, eligible patients were stratified by the baseline International Prostate Symptom Score (IPSS) and randomised (1:1:1) to receive FDC dutasteride 0.5 mg/tadalafil 5 mg (FDC 0.5/5 mg), dutasteride 0.5 mg, or tadalafil 5 mg for 48 weeks. The primary endpoint was the change in total IPSS from baseline to Week 48. Efficacy and safety were assessed at 4, 12, 24, 36, and 48 weeks. RESULTS: In total, 619 patients were analysed for efficacy. The least squares (LS) mean (standard error [se]) change in total IPSS at 48 weeks from baseline was -9.49 (0.37) for the FDC 0.5/5 mg group vs -4.40 (0.37) for dutasteride 0.5 mg group (LS mean difference [LSMD] -5.09, 95% confidence interval [CI] -6.13 to -4.50; P < 0.001), and -9.53 (0.36) for the FDC 0.5/5 mg group vs -4.24 (0.37) for tadalafil 5 mg group (LSMD -5.29, 95% CI -6.30 to -4.27; P < 0.001). The FDC 0.5/5 mg group demonstrated the most pronounced improvement in quality of life. Although the maximum urinary flow rate and post-void residual volume improved in all groups, differences were not statistically significant. In the comparison between the FDC 0.5/5 mg and dutasteride 0.5 mg groups, the LSMD (95% CI) of change from baseline to Week 48 in the international index of erectile function - erectile function (IIEF - EF) total score was 4.03 (2.35 to -5.71) (P < 0.05). Among the 655 patients analysed for safety, treatment-emergent adverse events occurred in 32.88% (FDC 0.5/5 mg) vs 21.20% (dutasteride 0.5 mg) and 26.48% (tadalafil 5 mg), with few serious adverse events observed. CONCLUSIONS: The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lee SW, Lee SH, Kim JH, et al. Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. BJU Int. 2026. PMID: 41667130. doi:10.1111/bju.70163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。